D-0160-2023 Class III Terminated
FDA drug recall D-0160-2023 was initiated by Lannett Company Inc. on November 9, 2022 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications The recall status is terminated (terminated June 8, 2023). Affected quantity: 5,640 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- January 25, 2023
- Initiation Date
- November 9, 2022
- Termination Date
- June 8, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5,640 bottles
Product Description
Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, 1000 Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 0527-1632-10
Reason for Recall
Failed Impurity/Degradation Specifications
Distribution Pattern
Nationwide USA
Code Information
Lots: 20256318A (12/2022), 20256321A (12/2022), 21000238A (01/2023)